Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
In this study, we did not find any profit brought by NCT in the stage I and stage IIa cohorts, but even more unfavorable outcomes appeared in the T1cN0M0 cohort. Therefore, whether the candidates of NCT should be extended to T1cN0M0 still need to be cautious.
Authors
- Chuangui Song (ORCID: https://orcid.org/0000-0002-3384-0634)
- Yushuai Yu (ORCID: https://orcid.org/0009-0002-2494-4981)
- Ruiliang Chen (ORCID: https://orcid.org/0009-0004-5608-1273)
- Weiwei Chen (ORCID: https://orcid.org/0000-0002-1965-7606)
- Wenfen Fu
- Jie Zhang (ORCID: https://orcid.org/0009-0004-5173-9996)
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Union Hospital (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1186/s40001-024-02139-1
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.86